BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanced Proteome Therapeutics Corporation Files Patent Application on Swift Linkage Multivalent Technology


10/20/2009 10:50:15 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 20, 2009) - In continuing efforts to advance the field of Protein Modification Technologies, Advanced Proteome Therapeutics ("APT") (TSX VENTURE: APC) has filed what it believes is a landmark patent application this month on inventions related to its Swift Linkage Multivalent Technology (SMLT). This Patent, along with previous discoveries, represents a milestone in the company's development and is a significant step toward commercialization.

Protein therapeutics is the fastest growing segment of the pharmaceutical market, with sales projected to be in the 75 billion dollar range by 2013. The Company feels it is well positioned, by virtue of discoveries related to SLMT, to capitalize on this growing market with its own internal projects as well as those of potential partners.

This advanced technology is currently being applied internally to protein targets aimed at treating cancer, Crohn's disease, arthritis, obesity, atherothrombosis and plaque rupture. In conjunction with the Company's internal progress, this patent filing allows the Company to foster relationships with potential partners, and/or customers that desire to utilize APT technology to further the development of their own programs.

The Company believes that the technology expands commercial opportunities for APT in certain subfields of protein therapeutics that have been especially challenging, providing APT with a competitive edge, and further validating its corporate strategy.

About Swift Linkage Multivalent Technology - Invented by APT to expand the repertoire of entities that can be rapidly linked to protein sites to generate products for development, the technology enables the rapid attachment of a desired entity to a modified site on a protein surface site-specifically, and to the fullest extent. SMLT has been demonstrated in several instances in APT programs to be capable of providing homogeneous products and may offer distinct technological advantages in the synthesis and manufacturing process of new protein therapeutics.

About Advanced Protein Therapeutics - APT is a pioneer and leader in the development of Protein Modification Technology which is directed toward altering proteins to improve their therapeutic and industrial potential. APT has created a broad platform technology applicable to a large variety of protein-based products to treat multiple areas of unmet medical need. The Company is applying its technology to the two fastest growing areas of therapeutics and diagnostics, Protein Drugs, and Personalized Medicine, respectively.

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.


Contacts:
Gale Capital Corporation
604.200 0103, ext. 272 (APC)
apc@galecapital.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES